|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.01 / 0.04|
ErgoD2 may be an important supplement to existing treatment for individuals suffering from chronic kidney disease (CKD), as an aid in the dietary management of the disease.
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") and its Clinical Research Organization (CRO) Ergomed plc (AIM:ERGO) today announced that they have expanded their co-development agreement with...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.